Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2006-08-31 · Food and Drug Administration, HHS · Notices

Notices. Notice

328 words·~1 min read·/register/2006/08/31/06-7310

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting; Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is announcing an amendment to the notice of a meeting of the Anti-Infective Drugs Advisory Committee. This meeting was announced in the **Federal Register** of July 25, 2006 (71 FR 42096). The amendment is being made to reflect a change in the *Date and Time* and *Agenda* portions of the document. The meeting scheduled for September 11, 2006, has been cancelled. There are no other changes. FOR FURTHER INFORMATION CONTACT: Sohail Mosaddegh, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: *sohail.mosaddegh@fda.hhs.gov* , or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington DC area), code 3014512530. Please call the Information Line for up-to-date information on this meeting. SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 25, 2006 (71 FR 42096), FDA announced that a meeting of the Anti-Infective Drugs would be held on September 11 and 12, 2006. On page 42096, in the second column, the *Date and Time* portion of the meeting is amended to read as follows: *Date and Time* : The meeting will held on September 12, 2006, from 8 a.m. to 5 p.m. On page 42096, third column, the *Agenda* portion of the meeting is amended to read as follows: *Agenda* : On September 12, 2006, the committee will discuss supplemental new drug application
(sNDA)21-158/S-006, FACTIVE (gemifloxacin mesylate) Tablets, submitted by Oscient Pharmaceuticals Corp., for the proposed treatment of acute baterial sinusitis. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees. Dated: August 25, 2006. Randall W. Lutter, Associate Commissioner for Policy and Planning. [FR Doc. 06-7310 Filed 8-30-06; 8:45 am]
Connections1 off-index
1 reference not yet in our index
  • 21 CFR 14
Citation graph
cites case law
Notices
Notice
Cite21 CFR 14
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.